New immunotherapy shot targets tumors with many mutations

NCT ID NCT04891198

Recruiting now Disease control Sponsor: 3D Medicines (Sichuan) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing Envafolimab, an immunotherapy drug given as a shot, in 126 adults with advanced solid tumors that have not responded to standard treatments. The study aims to see if patients with a high number of tumor mutations respond better than those with fewer mutations. Researchers hope to find a cutoff value to guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Envafolimab (a cancer immunotherapy drug given as a shot under the skin)
What this could lead to: If successful, this could help identify which patients with advanced solid tumors are most likely to benefit from Envafolimab based on their tumor's mutation level.
What could go wrong: This is an early-phase, single-arm study with no placebo group, so results may not be definitive. The drug may not work for all tumor types, and side effects from immunotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.